* This is the Professional Version. *
Chlamydial, Mycoplasmal, and Ureaplasmal Mucosal Infections
Sexually transmitted urethritis, cervicitis, proctitis, and pharyngitis not due to gonorrhea are caused predominantly by chlamydiae and infrequently by mycoplasmas or Ureaplasma sp. Chlamydiae may also cause salpingitis, epididymitis, perihepatitis, neonatal conjunctivitis, and infant pneumonia. Untreated chlamydial salpingitis can become chronic, causing minimal symptoms but having serious consequences. Diagnosis is by culture, immunoassay for antigens, or nucleic acid–based tests. Treatment is with single-dose azithromycin or a week of ofloxacin, levofloxacin, erythromycin, or a tetracycline.
Several organisms can cause nongonococcal sexually transmitted cervicitis in women and urethritis, proctitis, and pharyngitis in both sexes. These organisms include Chlamydia trachomatis (responsible for about 50% of such cases of urethritis and most cases of mucopurulent cervicitis), Mycoplasma genitalium, Ureaplasma urealyticum, and Trichomonas vaginalis (see Trichomoniasis). Chlamydiae may also cause lymphogranuloma venereum (see Lymphogranuloma Venereum (LGV)). Older, imprecise terms, such as "nonspecific urethritis” and “nongonococcal urethritis,” have been replaced by terms that specify the causative organism.
Men develop symptomatic urethritis after a 7- to 28-day incubation period, usually beginning with mild dysuria, discomfort in the urethra, and a clear to mucopurulent discharge. Discharge may be slight, and symptoms may be mild but are frequently more marked early in the morning; then, the urethral meatus is often red and blocked with dried secretions, which may also stain underclothes. Occasionally, onset is more acute and severe, with severe dysuria, frequency, and a copious, purulent discharge that simulates gonococcal urethritis. Infection may progress to epididymitis. After rectal or orogenital contact with an infected person, proctitis or pharyngitis may develop.
Women are usually asymptomatic, although vaginal discharge, dysuria, increased urinary frequency and urgency, pelvic pain, dyspareunia, and symptoms of urethritis may occur. Cervicitis with yellow, mucopurulent exudate and cervical ectopy (expansion of the red endocervical epithelium onto the vaginal surfaces of the cervix) are characteristic. Pelvic inflammatory disease (salpingitis and pelvic peritonitis) may cause lower abdominal discomfort (typically bilateral) and marked tenderness when the abdomen, adnexa, and cervix are palpated. Long-term consequences of PID include ectopic pregnancy and infertility. Fitz-Hugh-Curtis syndrome (perihepatitis) may cause right upper quadrant pain, fever, and vomiting.
Chlamydiae may be transferred to the eye, causing acute conjunctivitis.
Reactive arthritis (see Reactive Arthritis) caused by immunologic reactions to genital and intestinal infections is an infrequent complication of chlamydial infections in adults. Reactive arthritis sometimes causes skin and eye lesions and noninfectious recurrent urethritis.
Infants born to women with chlamydial cervicitis may develop chlamydial pneumonia or ophthalmia neonatorum (neonatal conjunctivitis—see Neonatal Conjunctivitis).
Chlamydial, mycoplasmal, or ureaplasmal infection is suspected in patients with symptoms of urethritis, salpingitis, cervicitis, or unexplained proctitis, but similar symptoms can also result from gonococcal infection. If clinical evidence for urethritis is uncertain, finding ≥ 5 WBCs/high-power field in a urine sample confirms the diagnosis. Examination of first-voided, morning samples is most sensitive.
Samples of cervical or vaginal specimens or male urethral or rectal exudates are obtained to check for chlamydiae. Commercially available nucleic acid–based tests (NAT) for chlamydial DNA may be done on nonamplified samples or samples amplified using one of several nucleic acid amplification techniques. Tests are usually done on swab samples, but nucleic acid amplification tests (NAAT) are highly sensitive and specific and can also be done on urine, eliminating the need for doing an uncomfortable swab of the urethra or cervix. Amplification techniques should be routinely used in patients at high risk (eg, unprotected sex with new or multiple partners, history of prior sexually transmitted disease [STD], exchanging sex for drugs or money).
Because other STDs (particularly gonococcal infection) often coexist, assays that detect gonococcal DNA should routinely be done, as should serologic testing for syphilis and HIV.
Detection of mycoplasmas and Ureaplasma sp is currently impractical in routine practice.
In the US, confirmed cases of chlamydial infection, gonorrhea, and syphilis must be reported to the public health system.
Urine testing using NAAT is especially useful for screening asymptomatic people at high risk of STDs because genital examination is not necessary. Screening recommendations vary by sex, age, sexual practices, and setting.
Nonpregnant women (including women who have sex with women) are screened annually if they
Pregnant women are screened during their initial prenatal visit; those ≤ 25 or with risk factors are screened again during the 3rd trimester.
Heterosexually active men are not screened except in settings with a high prevalence of chlamydial infection, including adolescent or STD clinics or at entrance into correctional facilities.
Men who have sex with men are screened if they have been sexually active within the previous year (for insertive intercourse, urine screen; for receptive intercourse, rectal swab; and for oral intercourse, pharyngeal swab).
(See also the US Preventive Services Task Force’s summary of recommendations regarding screening for chlamydial infection .)
Uncomplicated documented or suspected chlamydial, ureaplasmal, or mycoplasmal infections are treated with one of the following:
Azithromycin (given as a single dose) is preferred to drugs that require multiple doses over 7 days.
For pregnant women, azithromycin 1 g po once should be used.
These regimens do not reliably treat gonorrhea, which coexists in many patients with chlamydial infections. Therefore, treatment should include a single dose of ceftriaxone 250 mg IM if gonorrhea has not been excluded.
Patients who relapse (about 10%) are usually coinfected with microbes that do not respond to antichlamydial therapy, or they were reinfected since treatment. They may require further diagnostic evaluation and repeated or longer (21 to 28 days) courses, and their current sex partners should be treated. Patients should abstain from sexual intercourse until they and their partners complete treatment.
If chlamydial genital infections are untreated, symptoms and signs subside within 4 wk in about two thirds of patients. However, in women, asymptomatic cervical infection may persist, resulting in chronic endometritis, salpingitis, or pelvic peritonitis and their sequelae—pelvic pain, infertility, and increased risk of ectopic pregnancy. Because chlamydial infections can have serious long-term consequences for women, even when symptoms are mild or absent, detecting the infection in women and treating them and their sex partners is crucial.
Sexually acquired chlamydial, mycoplasmal, and ureaplasmal infections may affect the urethra, cervix, adnexa, throat, or rectum.
Diagnose using nucleic acid amplification tests.
Also test for coinfection with other STDs, including gonorrhea, syphilis, and HIV infection.
Screen high-risk, asymptomatic patients for chlamydial infection.
Use an antibiotic regimen that also treats gonorrhea if it has not been excluded.
Drug NameSelect Trade
levofloxacinIQUIX, LEVAQUIN, QUIXIN
* This is a professional Version *